171 related articles for article (PubMed ID: 24277755)
1. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants.
Jervis S; Song H; Lee A; Dicks E; Tyrer J; Harrington P; Easton DF; Jacobs IJ; Pharoah PP; Antoniou AC
J Med Genet; 2014 Feb; 51(2):108-13. PubMed ID: 24277755
[TBL] [Abstract][Full Text] [Related]
2. Familial relative risks for breast cancer by pathological subtype: a population-based cohort study.
Mavaddat N; Pharoah PD; Blows F; Driver KE; Provenzano E; Thompson D; Macinnis RJ; Shah M; ; Easton DF; Antoniou AC
Breast Cancer Res; 2010; 12(1):R10. PubMed ID: 20146796
[TBL] [Abstract][Full Text] [Related]
3. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
[TBL] [Abstract][Full Text] [Related]
4. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
[TBL] [Abstract][Full Text] [Related]
6. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Lee JS; John EM; McGuire V; Felberg A; Ostrow KL; DiCioccio RA; Li FP; Miron A; West DW; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):359-63. PubMed ID: 16492929
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
8. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.
Song H; Cicek MS; Dicks E; Harrington P; Ramus SJ; Cunningham JM; Fridley BL; Tyrer JP; Alsop J; Jimenez-Linan M; Gayther SA; Goode EL; Pharoah PD
Hum Mol Genet; 2014 Sep; 23(17):4703-9. PubMed ID: 24728189
[TBL] [Abstract][Full Text] [Related]
9. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
11. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.
Jervis S; Song H; Lee A; Dicks E; Harrington P; Baynes C; Manchanda R; Easton DF; Jacobs I; Pharoah PP; Antoniou AC
J Med Genet; 2015 Jul; 52(7):465-75. PubMed ID: 26025000
[TBL] [Abstract][Full Text] [Related]
12. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
Reedy M; Gallion H; Fowler JM; Kryscio R; Smith SA
Gynecol Oncol; 2002 May; 85(2):255-9. PubMed ID: 11972384
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
14. Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.
Girardi F; Barnes DR; Barrowdale D; Frost D; Brady AF; Miller C; Henderson A; Donaldson A; Murray A; Brewer C; Pottinger C; Evans DG; Eccles D; ; Lalloo F; Gregory H; Cook J; Eason J; Adlard J; Barwell J; Ong KR; Walker L; Izatt L; Side LE; Kennedy MJ; Tischkowitz M; Rogers MT; Porteous ME; Morrison PJ; Eeles R; Davidson R; Snape K; Easton DF; Antoniou AC
Genet Med; 2018 Dec; 20(12):1575-1582. PubMed ID: 29565421
[TBL] [Abstract][Full Text] [Related]
15. Identification of six new susceptibility loci for invasive epithelial ovarian cancer.
Kuchenbaecker KB; Ramus SJ; Tyrer J; Lee A; Shen HC; Beesley J; Lawrenson K; McGuffog L; Healey S; Lee JM; Spindler TJ; Lin YG; Pejovic T; Bean Y; Li Q; Coetzee S; Hazelett D; Miron A; Southey M; Terry MB; Goldgar DE; Buys SS; Janavicius R; Dorfling CM; van Rensburg EJ; Neuhausen SL; Ding YC; Hansen TV; Jønson L; Gerdes AM; Ejlertsen B; Barrowdale D; Dennis J; Benitez J; Osorio A; Garcia MJ; Komenaka I; Weitzel JN; Ganschow P; Peterlongo P; Bernard L; Viel A; Bonanni B; Peissel B; Manoukian S; Radice P; Papi L; Ottini L; Fostira F; Konstantopoulou I; Garber J; Frost D; Perkins J; Platte R; Ellis S; ; Godwin AK; Schmutzler RK; Meindl A; Engel C; Sutter C; Sinilnikova OM; ; Damiola F; Mazoyer S; Stoppa-Lyonnet D; Claes K; De Leeneer K; Kirk J; Rodriguez GC; Piedmonte M; O'Malley DM; de la Hoya M; Caldes T; Aittomäki K; Nevanlinna H; Collée JM; Rookus MA; Oosterwijk JC; ; Tihomirova L; Tung N; Hamann U; Isaccs C; Tischkowitz M; Imyanitov EN; Caligo MA; Campbell IG; Hogervorst FB; ; Olah E; Diez O; Blanco I; Brunet J; Lazaro C; Pujana MA; Jakubowska A; Gronwald J; Lubinski J; Sukiennicki G; Barkardottir RB; Plante M; Simard J; Soucy P; Montagna M; Tognazzo S; Teixeira MR; ; Pankratz VS; Wang X; Lindor N; Szabo CI; Kauff N; Vijai J; Aghajanian CA; Pfeiler G; Berger A; Singer CF; Tea MK; Phelan CM; Greene MH; Mai PL; Rennert G; Mulligan AM; Tchatchou S; Andrulis IL; Glendon G; Toland AE; Jensen UB; Kruse TA; Thomassen M; Bojesen A; Zidan J; Friedman E; Laitman Y; Soller M; Liljegren A; Arver B; Einbeigi Z; Stenmark-Askmalm M; Olopade OI; Nussbaum RL; Rebbeck TR; Nathanson KL; Domchek SM; Lu KH; Karlan BY; Walsh C; Lester J; ; ; Hein A; Ekici AB; Beckmann MW; Fasching PA; Lambrechts D; Van Nieuwenhuysen E; Vergote I; Lambrechts S; Dicks E; Doherty JA; Wicklund KG; Rossing MA; Rudolph A; Chang-Claude J; Wang-Gohrke S; Eilber U; Moysich KB; Odunsi K; Sucheston L; Lele S; Wilkens LR; Goodman MT; Thompson PJ; Shvetsov YB; Runnebaum IB; Dürst M; Hillemanns P; Dörk T; Antonenkova N; Bogdanova N; Leminen A; Pelttari LM; Butzow R; Modugno F; Kelley JL; Edwards RP; Ness RB; du Bois A; Heitz F; Schwaab I; Harter P; Matsuo K; Hosono S; Orsulic S; Jensen A; Kjaer SK; Hogdall E; Hasmad HN; Azmi MA; Teo SH; Woo YL; Fridley BL; Goode EL; Cunningham JM; Vierkant RA; Bruinsma F; Giles GG; Liang D; Hildebrandt MA; Wu X; Levine DA; Bisogna M; Berchuck A; Iversen ES; Schildkraut JM; Concannon P; Weber RP; Cramer DW; Terry KL; Poole EM; Tworoger SS; Bandera EV; Orlow I; Olson SH; Krakstad C; Salvesen HB; Tangen IL; Bjorge L; van Altena AM; Aben KK; Kiemeney LA; Massuger LF; Kellar M; Brooks-Wilson A; Kelemen LE; Cook LS; Le ND; Cybulski C; Yang H; Lissowska J; Brinton LA; Wentzensen N; Hogdall C; Lundvall L; Nedergaard L; Baker H; Song H; Eccles D; McNeish I; Paul J; Carty K; Siddiqui N; Glasspool R; Whittemore AS; Rothstein JH; McGuire V; Sieh W; Ji BT; Zheng W; Shu XO; Gao YT; Rosen B; Risch HA; McLaughlin JR; Narod SA; Monteiro AN; Chen A; Lin HY; Permuth-Wey J; Sellers TA; Tsai YY; Chen Z; Ziogas A; Anton-Culver H; Gentry-Maharaj A; Menon U; Harrington P; Lee AW; Wu AH; Pearce CL; Coetzee G; Pike MC; Dansonka-Mieszkowska A; Timorek A; Rzepecka IK; Kupryjanczyk J; Freedman M; Noushmehr H; Easton DF; Offit K; Couch FJ; Gayther S; Pharoah PP; Antoniou AC; Chenevix-Trench G;
Nat Genet; 2015 Feb; 47(2):164-71. PubMed ID: 25581431
[TBL] [Abstract][Full Text] [Related]
16. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
[TBL] [Abstract][Full Text] [Related]
17. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
18. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Evans DG; Shenton A; Woodward E; Lalloo F; Howell A; Maher ER
BMC Cancer; 2008 May; 8():155. PubMed ID: 18513387
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; McGuffog L; Barrowdale D; Lee A; Soucy P; Dennis J; Domchek SM; Robson M; Spurdle AB; Ramus SJ; Mavaddat N; Terry MB; Neuhausen SL; Schmutzler RK; Simard J; Pharoah PDP; Offit K; Couch FJ; Chenevix-Trench G; Easton DF; Antoniou AC
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376175
[TBL] [Abstract][Full Text] [Related]
20. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
